Bupropion

Drugs of Today

Volumn 42, Issue 10, 2006, Pages 671-681

  Wilkes, Scott ^a  

^a UNIVERSITY OF SUNDERLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIMALARIAL AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; ERYTHROMYCIN; FLECAINIDE; METHYLPHENIDATE; NEUROLEPTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; PROPAFENONE; QUINOLONE DERIVATIVE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; THEOPHYLLINE; THIORIDAZINE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ABNORMAL DREAMING; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ANXIETY; ASTHENIA; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONCENTRATION LOSS; CONFUSION; CONSTIPATION; COORDINATION DISORDER; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIZZINESS; DOPAMINERGIC SYSTEM; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FLUSHING; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HALLUCINATION; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; INSOMNIA; IRRITABILITY; MAJOR DEPRESSION; NAUSEA; NORADRENERGIC SYSTEM; PREGNANCY; PRURITUS; PSORIASIS; RASH; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SIDE EFFECT; SMOKING CESSATION; STEVENS JOHNSON SYNDROME; SWEATING; TACHYCARDIA; TASTE DISORDER; THORAX PAIN; TINNITUS; TREMOR; URINARY FREQUENCY; URINE RETENTION; VISUAL DISORDER; WEIGHT GAIN; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; DIZZINESS; HEADACHE; HUMANS; MODELS, BIOLOGICAL; NAUSEA; SLEEP INITIATION AND MAINTENANCE DISORDERS; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 33845440828     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2006.42.10.1025701     Document Type: Review

References (83)

1. Fava, M., Rush, A.J., Thase, M.E. et al. 15 Years of experience with bupropion HCL: From bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry 2005, 7: 106-13.
2. Tong, E.K., Carmody, T.P., Simon, J.A. Bupropion for smoking cessation. A review. Compr Ther 2006, 32: 26-33.
3. GlaxoSmithKline. Zyban® (bupropion hydrochloride) sustained release tablets. Product information, http://us.gsk.com/product/assets/us_ zyban.pdf, accessed August 4, 2006.
4. Warner, C., Shoaib, M. How does bupropion work as a smoking cessation aid? Addict Biol 2005, 10: 219-31.
5. Jefferson, J.W., Pradko, J.F., Muir, K.T. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Clin Ther 2005, 27: 1685-95.
6. Rau, K.S., Birdsall, E., Hanson, J.E. et al. Bupropion increases striatal vesicular monoamine transport. Neuropharmacology 2005, 49: 820-30.
7. Stahl, S.M., Pradko, J.F., Haight, B.R. et al. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. J Clin Psychiatry 2004, 6: 159-66.
8. Stolerman, I.P., Shoaib, M. The neurobiology of tobacco addiction. Trends Pharmacol Sci 1991, 12: 467-73.
9. Miller, D.K., Sumithran, S.P., Dwoskin, L.P. Bupropion inhibits [(3)H]overflow from rat striatal slices preloaded with [(3H)]dopamine and from rat hippocampal slices preloaded with [(3H)] norepinephrine. J Pharmacol Exp Ther 2002, 302: 1113-22.
10. Argyelan, M., Szabo, Z., Kanyo, B. et al. Dopamine transporter availability in medication-free and in bupropion-treated depression: A 99mTc-TRODAT-1 SPECT study. J Affect Disord 2005, 89: 115-23.
11. Rush, A.J., Trivedi, M.H., Wisniewski, S.R. et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006, 354: 1231-42.
12. Zisook, S., Rush, A.J., Haight, B.R., Clines, D.C., Rockett, C.B. Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry 2006, 59: 203-10.
13. Modell, J.G., Rosenthal, N.E., Harriett, A.E. et al. Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL. Biol Psychiatry 2005, 58: 658-67.
14. Nonacs, R.M., Soares, C.N., Viguera, A.C., Pearson, K., Poitras, J.R., Cohen, L.S. Bupropion SR for the treatment of postpartum depression: A pilot study. Int J Neuropsychopharmacol 2005, 8: 445-9.
15. Hurt, R.D., Sachs, D.P., Glover, E.D. et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997, 337: 1195-202.
16. Jorenby, D.E., Leischow, S.J., Nides, M.A. et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999, 340: 685-91.
17. Holmes, S., Zwar, N., Jiménez-Ruiz, C.A. et al. Bupropion as an aid to smoking cessation: A review of real-life effectiveness. Int J Clin Pract 2004, 58: 285-91.
18. Paluck, E.C., McCormack, J.P., Ensom, M.H., Levine, M., Soon, J.A., Fielding, D.W. Outcomes of bupropion therapy for smoking cessation during routine clinical use. Ann Pharmacother 2006, 40: 185-90.
19. Wilkes, S., Evans, A., Henderson, M., Gibson, J. Pragmatic, observational study of bupropion treatment for smoking cessation in general practice. Postgrad Med J 2005, 81: 719-22.
20. Tonnesen, P., Tonstad, S., Hjalmarson, A. et al. A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. J Intern Med 2003, 254: 184-92.
21. Hughes, J., Stead, L., Lancaster, T. Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews 2004, CD000031.
22. Gonzales, D.H., Nides, M.A., Ferry, L.H. et al. Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: A randomized placebo-controlled study. Clin Pharmacol Ther 2001, 69: 438-44.
23. National Institute for Clinical Excellence. Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation. NICE 2002, 39.
24. Boardman, T., Catley, D., Mayo, M.S., Ahluwalia, U.S. Self-efficacy and motivation to quit during participation in a smoking cessation program. Int J Behav Med 2005, 12: 266-72.
25. Errard-Lalande, G. Assisting smoking cessation. Revue des Maladies Respiratoires 2005, 22: 8S15-8S26.
26. Hughes, J.R., Carpenter, M.J. The feasibility of smoking reduction: An update. Addiction 2005, 100: 1074-89.
27. Rauhut, A.S., Dwoskin, L.P., Bardo, MT. Tolerance does not develop to the decrease in nicotine self-administration produced by repeated bupropion administration. Nicotine Tob Res 2005, 7: 901-7.
28. Killen, J.D., Fortmann, S.P., Murphy, G.M. Jr. et al. Extended treatment with bupropion SR for cigarette smoking cessation. J Consult Clin Psychol 2006, 74: 286-94.
29. Hatsukami, D.K., Rennard, S., Patel, M.K. et al. Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking. Am J Med 2004, 116: 151-7.
30. Al Koudsi, N., Tyndale, R.F. Genetic influences on smoking: A brief review. Ther Drug Monit 2005, 27: 704-9.
31. Lerman, C., Jepson, C., Wileyto, E.P. et al. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: Results of two randomized clinical trials. Neuropsychopharmacology 2006, 31: 231-42.
32. Catley, D., Harris, K.J., Okuyemi, K.S., Mayo, M.S., Pankey, E., Ahluwalia, J.S. The influence of depressive symptoms on smoking cessation among African Americans in a randomized trial of bupropion. Nicotine Tob Res 2005, 7: 859-70.
33. Clark, M.M., Hurt, R.D., Croghan, I.T., et al. The prevalence of weight concerns in a smoking abstinence clinical trial. Addict Behav 2005, 31: 1144-52.
34. Wagena, E.J., Knipschild, P.G., Huibers, M.J., Wouters, E.F., van Schayck, C.P. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch Intern Med 2005, 165: 2286-92.
35. Tashkin, D., Kanner, R., Bailey, W. et al. Smoking cessation in patients with chronic obstructive pulmonary disease: A double-blind, placebo-controlled, randomised trial. Lancet 2001, 357: 1571-5.
36. Paganelli, M.O., Tanus-Santos, J.E., Sabha, M. et al. Hemodynamic effects of bupropion in anesthetized dogs. Eur J Pharmacol 2006, 530: 124-7.
37. World Health Organisation. The World Health Report 1999.
38. Tonstad, S., Farsang, C., Klaene, G. et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: A multicentre, randomised study. Eur Heart J 2003, 24: 946-55.
39. Ludvig, J., Miner, B., Eisenberg, M.J. Smoking cessation in patients with coronary artery disease. Am Heart J 2005, 149: 565-72.
40. Evins, A.E., Cather, C., Deckersbach, T. et al. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol 2005, 25: 218-25.
41. Brustolim, D., Ribeiro-dos-Sontos, R., Kast, R.E., Altschuler, E.L., Soares, M.B. A new chapter opens in anti-inflammatory treatments: The antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int Immunopharmacol 2006, 6: 903-7.
42. Kast, R.E. Evidence of a mechanism by which etanercept increased TNF-alpha in multiple myeloma: New insights into the biology of TNF-alpha giving new treatment opportunities - the role of bupropion. Leuk Res 2005, 29: 1459-63.
43. Kast R.E., Altschuler E.L. Bupropion and chronic aphthous ulceration. Arch Dermatol 2005, 141: 1167.
44. Biederman, J., Arnsten, A.F., Faraonem S.V. et al. New developments in the treatment of ADHD. J Clin Psychiatry 2006, 67: 148-59.
45. Pityaratstian, N., Pityaratstian, N. Advances in alternative pharmacotherapy of ADHD. J Med Associat Thailand 2005, 88 (Suppl. 4): S357-62.
46. Himpel, S., Banaschewski, T., Heise, C.A., Rothenberger, A. The safety of nonstimulant agents for the treatment of attention-deficit hyperactivity disorder. Expert Opin Drug Saf 2005, 4: 311-21.
47. Waxmonsky, J.G. Nonstimulant therapies for attention-deficit hyperactivity disorder (ADHD) in children and adults. Essent Psychopharmacol 2005, 6: 262-76.
48. Solhkhah, R., Wilens, T.E., Daly, J., Prince, J.B., Van Patten, S.L., Biederman, J. Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit/hyperactivity disorder and mood disorders. J Child Adolesc Psychopharmacol 2005, 15: 777-86.
49. Levin, F.R., Evans, S.M., Brooks, D.J., Kalbag, A.S., Garawi, F., Nunes, E.V. Treatment of methadone-maintained patients with adult AD-HD: Double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend 2006, 81: 137-48.
50. Dannon, P.N., Lowengrub, K., Musin, E., Gonopolski, Y., Kotler, M. Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: A preliminary blind-rater study. J Clin Psychopharmacol 2005, 25: 593-6.
51. Newton, T.F., Roache, J.D., De La Garza, R. 2nd et al. Safety of intravenous methamphetamine administration during treatment with bupropion. Psychopharmacology (Berl) 2005, 182: 426-35.
52. Joshi, D., Naidu, P.S., Singh, A., Kulkarni, S.K. Reversal of triazolam tolerance and withdrawal-induced hyperlocomotor activity and anxiety by bupropion in mice. Pharmacology 2005, 75: 93-7.
53. Poling, J., Oliveto, A., Petry, N. et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry 2006, 63: 219-28.
54. Katz, J., Pennella-Vaughan, J., Hetzel, R.D., Kanazi, G.E., Dworkin, R.H. A randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain. J Pain 2005, 6: 656-61.
55. Kim, S.W., Shin, I.S., Kim, J.M., Yang, S.J., Shin, H.Y., Yoon, J.S. Bupropion may improve restless legs syndrome: A report of three cases. Clin Neuropharmacol 2005, 28: 298-301.
56. Barrueco, M., Otero, M.J., Palomo, L. et al. Adverse effects of pharmacological therapy for nicotine addiction in smokers following a smoking cessation program. Nicotine Tob Res 2005, 7: 335-42.
57. Hubbard, R., Lewis, S., West, J. et al. Bupropion and the risk of sudden death: A self-controlled case-series analysis using The Health Improvement Network. Thorax 2005, 60: 848-50.
58. Swan, G.E., McAfee, T., Curry, S.J. et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: A randomized trial. Arch Intern Med 2003, 163: 2337-44.
59. Cassis, T.B., Callen, J.P. Bupropion-induced subacute cutaneous lupus erythematosus. Australas J Dermatol 2005, 46: 266-9.
60. Kotlyar, M., Brauer, L.H., Tracy, T.S. et al. Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol 2005, 25: 226-9.
61. Wang, J.S., DeVane, C.L., Gibson, B.B., Donovan, J.L., Markowitz, J.S., Zhu, H.J. Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice. Psychopharmacology (Berl) 2006, 183: 490-9.
62. Anonymous. Bupropion to aid smoking cessation. Drug Ther Bull 2000, 38: 73-5.
63. George, A.K., Kunwar, A.R., Awasthi, A. Acute myocardial infarction in a young male on methylphenidate, bupropion, and erythromycin. J Child Adolesc Psychopharmacol 2005, 15: 693-5.
64. Ginzburg, R., Wong, Y., Fader, J.S. Effect of bupropion on sexual dysfunction. Ann Pharmacother 2005, 39: 2096-9.
65. Kennedy, S.H., Fulton, K.A., Bagby, R.M., Greene, A.L., Cohen, N.L., Rafi-Tari, S. Sexual function during bupropion or paroxetine treatment of major depressive disorder. Can J Psychiatry 2006, 51: 234-42.
66. Bupropion (amfebutamone): Caution during pregnancy. Prescrire International 2005, 14: 225.
67. Curry, S.C., Kashani, J.S., LoVecchio, F., Holubek, W. Intraventricular conduction delay after bupropion overdose. J Emerg Med 2005, 29: 299-305.
68. Shepherd, G. Adverse effects associated with extra doses of bupropion. Pharmacotherapy 2005, 25: 1378-82.
69. Ross, S., Williams, D. Bupropion: Risks and benefits. Expert Opin Drug Saf 2005, 4: 995-1003.
70. Bolin, K., Lindgren, B., Willers, S. The cost utility of bupropion in smoking cessation health programs: Simulation model results for Sweden. Chest 2006, 129: 651-60.
71. Woolacott, N.F., Jones, L., Forbes, C.A. et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: A systematic review and economic evaluation. Health Technol Assess 2002, 6(16): 1-245.
72. Holt, S., Harwood, M., Aldington, S., Beasley, R. PHARMAC and tobacco control in New Zealand: Government policy "up in smoke". N Z Med J 2005, 118: U1502.
73. Bloomfield, A. Buproprion, public funding, and smoking cessation. N Z Med J 2005, 118: U1576.
74. Corelli, R.L., Hudmon, K.S. Pharmacologic interventions for smoking cessation. Crit Care Nurs Clin North Am 2006, 18: 39-51.
75. Hall, S.M., Lightwood, J.M., Humfleet, G.L., Bostrum, A., Reus, V.I., Muñoz, R. Cost-effectiveness of bupropion, nortriptyline, and psychological intervention in smoking cessation. J Behav Health Serv Res 2005, 32: 381-92.
76. Department of Health. Statistics on NHS Stop Smoking services in England, April 2005 to March 2006. http://www.ic.nhs.uk/pubs/ nhsstopsmokingstats2005to2006q4.
77. Davis, J.M. Tobacco cessation for the dental team: A practical guide part II. Evidence-based interventions. J Contemp Dent Pract 2005, 6: 178-86.
78. Nasry, H.A., Preshaw, P.M., Stacey, F., Heasman, L., Swan, M., Heasman, P.A. Smoking cessation advice for patients with chronic periodontitis. Br Dent J 2006, 200: 272-75.
79. Covington, L.L., Breault, L.G., O'Brien, J.J., Hatfield, C.H., Vasquez, S.M., Lutka, R.W. An innovative tobacco use cessation program for military dental clinics. J Contemp Dent Pract 2005, 6: 151-63.
80. Pizzo, G., Piscopo, M.R., Pizzo, I., Giuliana, G. Smoking cessation counselling and dental team. Ann Ig 2006, 18: 155-70.
81. Mansourati, J., Borel, M.L., Munier, S., Guevel-Jointret, A.L. Medications in smoking cessation. Presse Med 2005, 34: 1331-6.
82. McRobbie, H., Lee, M., Juniper, Z. Non-nicotine pharmacotherapies for smoking cessation. Respir Med 2005, 99: 1203-12.
83. Neubeck, L. Smoke-free hospitals and the role of smoking cessation services. Br J Nurs 2006, 15: 248-51.